Cannabis Law Report

DECEMBER 27, 2019

If you thought there was no relationship between cannabis use and technology, consider these stats: the average number of mobile apps being used in a day by current cannabis users are 4. However, the costs of conducting a full-scale clinical trial can be prohibitive, posing barriers to research for cannabis companies.

Clinical Trials 85

Clinical Trials Access Research and Development Supply Chain 85

Cannabis Law Report

AUGUST 3, 2021

Many mental health disorders have treatment options, but they aren’t nearly as safe and efficacious as conventional pharmaceuticals or therapies. CSE: MXT) (OTCQB: MXTTF) aims to address these problems by pairing biometric interviews with brainwave data to create a proprietary mental health reference database. (CSE:

Research and Development 105

Research and Development Data Conditions Therapy 105

Cannabis Law Report

JUNE 2, 2021

The latest article in Healthcare Business Today cites the company’s Multiomics Advanced Technology™ (MAT) as the driver for more accurate predictions about disease states and individual responses to diseases and treatments that will make medicine truly personalized. www.GATCHealth.com. Disclaimer.

Medicine 90

Medicine Business Treatment Data 90

The Cannigma

JULY 1, 2022

There’s no doubt that the amount of information that is available about cannabis is at an all-time high – in 2020 alone, over 3,500 scientific articles were published on the topic. Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. The cannabis problem.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

NOVEMBER 23, 2021

The new patent, US Patent No 11,180,517, covers methods of treating treatment-resistant depression (TRD) with crystalline psilocybin as well as with oral dosage forms of crystalline psilocybin with an excipient. This is COMPASS’s 10 th patent overall, with five now granted in the US, two in the UK, one in Germany and two in Hong Kong.

Clinical Trials 52

Clinical Trials Therapy Research and Development Media 52

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. On track to report top-line data by end of 2021. Net loss for the six months ended 30 June 2021 was $30.2 million, or $0.79 million) compared with $24.8 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Veriheal

AUGUST 17, 2021

A recent study from the University of Pittsburgh suggests that the United States federal government’s current stance that cannabis is a gateway drug is bunk. Cannabis is a gateway drug is nothing more than another Reefer Madness propaganda tactic. It is just about as old as cannabis prohibition itself.

Data 98

Data Cannabis Media Collective 98

Cannabis Law Report

SEPTEMBER 20, 2021

KWC is a limited liability corporation formed under the laws of Arizona , which operates 10 ketamine infusion treatment clinics, across Arizona , Colorado , Florida , Illinois , Minnesota , Nevada , Texas , and Washington. Transaction Highlights.

Treatment 52

Treatment Media Research and Development Patients 52

Cannabis Law Report

JULY 22, 2021

We believe that this will serve as a strong platform from which to deploy impactful alternative and psychedelic based treatment options,” stated Pouya Farmand, Chief Executive Officer of Levitee. Levitee Media Contact. media@leviteelabs.com. About Levitee Labs. The CSE (operated by CNSX Markets Inc.) ir@leviteelabs.com.

eCommerce 105

eCommerce Therapy Media Access 105

Cannabis Law Report

DECEMBER 26, 2021

The patent relates to improved technology for detection and maintenance of the optimal therapeutic psychedelic state, which Entheon intends to study through the monitoring of electroencephalogram (EEG) biomarkers in order to optimize the treatment of neuropsychiatric conditions. US Provisional Patent Filed. About Entheon Biomedical Corp.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

NOVEMBER 9, 2021

(“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), a leader in new medicines and treatments for a modern world, today announced the official, completed acquisition of Ketamine Wellness Centers Arizona LLC (“KWC”), becoming the largest chain of wellness centers providing ketamine treatments in the U.S.

Treatment 52

Treatment Therapy Media Access 52

CannaMD

MAY 19, 2020

In a working draft of research prepared by Canadian scientists, study authors claim that their findings are “crucial for the future analysis of the effects of medical cannabis on COVID-19.” And then something interesting happened: Serendipitously, we noted that cannabis may also affect ACE2. COVID-19 Basics: ACE2.

Research and Development 131

Research and Development Sativa Marijuana Extraction 131

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). For media inquiries please contact: Michael Sharp.

DEA 66

DEA Clinical Trials THC Research and Development 66

Freedom Leaf

JANUARY 4, 2018

“Our goal is to bring awareness of emerging innovation and opportunities to the East Coast regarding cannabis technology.” Cofounder, Jade Insights and Cannabis Tech Group, New York, N.Y. It’s a software platform that helps cannabis businesses augment their process by providing insights for data-backed decision-making.

Data 60

Data Policy Media Cannabis 60

Cannabis Law Report

JULY 6, 2021

Johnson’s primary area of research expertise is the psychopharmacology of medications for treating addictions, and he is well known in the field for his discovery that topiramate, a gamma-aminobutyric acid (GABA) facilitator and glutamate antagonist, an effective treatment for alcoholism. ” About Ehave, Inc. Ehave, Inc.

Research and Development 97

Research and Development Wellness and Beauty Clinical Trials Therapy 97

Cannabis Law Report

SEPTEMBER 15, 2021

Delta-8 tetrahydrocannabinol, also known as delta-8 THC, is a psychoactive substance found in the Cannabis sativa plant, of which marijuana and hemp are two varieties. Delta-8 THC is one of over 100 cannabinoids produced naturally by the cannabis plant but is not found in significant amounts in the cannabis plant.

THC 105

THC Pets Events Hemp 105

Cannabis Law Report

OCTOBER 15, 2021

The presentation details the identification of a novel locus on chromosome 14 which is associated with proteinuric kidney disease and includes data which confirms the well-known association of APOL1 risk haplotypes (i.e., New data supporting the use of machine learning and electronic health records to predict DN in patients with diabetes. “In

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

Cannabis Law Report

OCTOBER 22, 2021

–The Company expects to hold a Research & Development event to review,these breakthrough findings in Q4 2021 that will be open to the public, shareholders, analysts and the media– TORONTO, CANADA – October 19, 2021 – Cybin Inc.

Research and Development 52

Research and Development Safety Media Data 52

Cannabis Law Report

JANUARY 24, 2022

Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. In 2022, we anticipate reading out interim data from our ongoing Phase 2 clinical trial of GFB-887, as well as initial data from our ongoing Phase 1 study of GFB-024.

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

MARCH 17, 2022

COVID-related border restrictions did not cause immediate major interruption to Australia’s drug markets, but wastewater data strongly indicates that the cumulative effect of these restrictions led to some substantial market interruptions. The latest report presents data on Australia’s drug consumption for 12 substances.

Consumption 52

Consumption Programs Data Treatment 52

CannaMD

NOVEMBER 6, 2019

Using Cannabis to Quit Opioids. Perhaps the commercialization of marijuana and the favorable media coverage surrounding the health effects of marijuana are fostering such a perception. Results further indicate that the presence of medicinal cannabis legislation appears to have no influence over opioid misuse. million to 11.4

Marijuana 88

Marijuana Patients Clinical Trials Data 88

Cannabis Law Report

SEPTEMBER 9, 2021

The current public policies in local and state cannabis ordinance and equity programs may enhance racial disparities if they follow the pattern of exclusion and criminalization that encompass past policies promoted as beneficial to African Americans but uphold racial capitalistic practices. Authored By: By Dr. Ayoka Nurse.

Policy 105

Policy Research and Development Collective Banking 105

Cannabis Law Report

JULY 24, 2019

Dr Mikael Sodergren , Managing Director and Academic Lead at Sapphire Medical Clinics said: “Medicinal cannabis is a new and exciting field. But it is important that access to it is delivered in a way that fits in with other treatment options.

Epilepsy 40

Epilepsy Medicine Treatment Patients 40

CannaMD

AUGUST 19, 2020

Can cannabis help treat the coronavirus? CannaMD takes a look at everything we know about cannabis and COVID-19 so far – separating science from spectacle, and highlighting key findings that might even surprise the most seasoned medical marijuana supporters. Coronavirus Basics. Terpenes and CBD: Twice as Effective.

Research and Development 141

Research and Development Marijuana Extraction Terpenes 141

Cannabis Law Report

JULY 29, 2021

We want to be an industry leader in preventing negative side effects during treatment and believe this can be of benefit to the entire industry.” HPPD is most commonly caused by LSD and Mushrooms, but also can be caused by MDMA, Cannabis, and even SSRIs. Unlocking the genetic link will help point us towards treatment and a cure.

Research and Development 105

Research and Development Conditions Data Patients 105

Veriheal

DECEMBER 27, 2022

Researchers recruited 641 participants from Western Europe and America via Facebook groups, university mailing lists, and social media forums. The subjective nature of self-reported data can plague research. The participants completed a survey asking about lifetime experiences with: Psychedelics (LSD, psilocybin, DMT, mescaline).

Research and Development 101

Research and Development Therapy Consumption DEA 101

Canna Law Blog

APRIL 13, 2019

The letters were sent “in response to their making unsubstantiated claims related to more than a dozen different products and spanning multiple product webpages, online stores and social media websites.” Specifically, the agency fears that. directions for use, warnings)?

CBD 90

CBD Safety Topical Food 90

Cannabis Law Report

DECEMBER 6, 2021

–(BUSINESS WIRE)–Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced the appointment of Jeff W. Jacobs, Ph.D. as Chief Scientific Officer (CSO). Dr. Jacobs, who most recently served as CSO of Ardelyx, Inc.,

Research and Development 52

Research and Development Supply Chain Clinical Trials Medicine 52

Cannabis Law Report

DECEMBER 9, 2021

These describe technology and infrastructure for the collection of precise, multimodal, multivalent data that can be processed via machine learning, artificial intelligence, signal processes, and other statistical methods to yield clinically meaningful output to satisfy the requirements of the IFU. Media Contact: media@mindmed.co.

Research and Development 52

Research and Development Clinical Trials Therapy Medicine 52

Veriheal

AUGUST 12, 2021

Funded by Realm of Caring —a non-profit organization committed to redefining cannabis through research and education—this study on CBD and epilepsy was carried out as part of a joint effort with Johns Hopkins University School of Medicine researchers. We look forward to the evolution of cannabis research in this area.

Epilepsy 81

Epilepsy Pharmaceutical Patients Sleep 81

The Blunt Truth

MAY 26, 2020

In his statement, Commissioner Hahn noted that the FDA was working on: 1) continuing to educate the public on the risks of CBD; 2) seeking reliable data on the safety and benefits of CBD, including opening the public docket on the matter; and 3) monitoring the marketplace for the sale and marketing of unapproved drugs.

CBD 103

CBD Hemp Programs Food 103

Cannabis Law Report

JANUARY 13, 2020

Additional pipeline: Commence Phase 2b study of a cannabidiol formulation for the treatment of schizophrenia. Continue to explore CBDV in autism through a combination of open-label and investigator-led placebo controlled clinical trials with data from one or more of these programs in 2020. Media Enquiries: Sam Brown Inc.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

MAY 6, 2022

COAs are generally issued by accredited laboratories and many states require sellers to include COAs with each cannabis or CBD product. The FDA’s warning letters tell the public that the FDA reads and reviews companies’ websites, labels, social media, and marketing language. High level CBD can help manage symptoms of psychosis.”.

THC 52

THC CBD Media Food 52

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. Doctors can prescribe Epidyolex – an oral solution of cannabidiol, which comes from the cannabis plant – if they think it will help sufferers. What is Epidyolex?

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

The Blunt Truth

AUGUST 13, 2019

To understand the breadth of issues and gather data on safety we have conducted a public hearing, reviewed the medical literature, and have an open public docket.”. The FDA is collecting data to fill these gaps. The FDA has historically been passive in its oversight of CBD products.

CBD 80

CBD Food Seed-To-Sale Wellness and Beauty 80

Cannabis Law Report

DECEMBER 14, 2021

NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the “Company”), announced today that it is the first company to formulate medical cannabis extract vaporizer pen products in a UK-based manufacturing premises, licensed and approved by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and Home Office.

Extraction 52

Extraction Patients Medicine Tincture 52

Cannabis Law Report

SEPTEMBER 13, 2021

Positive data from this important study would significantly advance MYMD-1’s potential to become a blockbuster drug for inflammation and aging.”. Because it can cross the blood-brain barrier, MYMD-1 is also positioned to be a possible treatment for multiple sclerosis and other brain-related disorders. Media: media@mymd.com.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52